Barry Cohen

Barry Cohen

Barry Cohen has nearly 30 years in communications and marketing, the majority in senior positions at three large international health care companies – Abbott Laboratories, Warner-Lambert (now part of Pfizer) and Bayer, Inc.

At Abbott, Cohen was a member of the company’s investor relations team, responsible for preparing all financial analyst presentations. He also oversaw the company’s award-winning annual and quarterly reports and was responsible for both the company’s investor seminar and annual shareholders’ meeting.

After relocating to Arizona, Cohen served as editor of M.D. News, a magazine for Phoenix-area physicians. Later he was a reporter for a weekly newspaper in a north Phoenix, where he specialized in business articles and profiles of local publicly traded companies.

To further his knowledge and understanding of financial markets, Cohen earned a series 7 broker’s license and was employed at Charles Schwab as a registered representative.  He returned to the communications field with CPRi Communications, where he wrote numerous case studies and bylined articles for the company’s clients in the health care information technology industry. Later, he worked for a Scottsdale, Ariz.-based investment bank preparing profiles of companies being offered for sale.

Recent Articles

Amgen Bids for a Return to Favor

Amgen's (AMGN) third-quarter earnings, budget management and full-year outlook turn positive, boosting the company's market prospects.

5 Potential Acquisition Targets in Medical Device Stocks

Big-name med-tech companies are looking to branch out in a $300 billion market. Here are five potential targets that could be swallowed up soon.

Cigna Deal Signals More Insurance Buyouts to Come

Smaller insurers are catching attention in the wake of expected consolidation.

Amgen Leads Firms In Pancreatic Cancer Drug Chase

Amgen (Nasdaq:AMGN) is among several pharmaceutical companies working on a treatment for pancreatic cancer, the deadly disease that recently felled both Steve Jobs of Apple…

Big Pharma Might Already Have Sights on Abbott Spinoff

Abbott's Humira is a dollar-printing temptation for several companies, but Pfizer's tofacitinib could change the rheumatoid arthritis drug landscape.